Tesaro's new ovarian drug will cost cancer patients $60,000 to $177,000 a year
UPDATE: Tesaro drug pricing snafu sends stock down 3% and lifts rival drugmaker's shares
UPDATE: Tesaro stock dives 7% after drug pricing snafu
UPDATE: This is the next big catalyst for Amazon's stock (and it's not the NFL)
This is the next big catalyst for Amazon's stock (and it's not the NFL)
Leafbuyer Goes Public
This article represents opinions of the author and not those of his firm and are subject to change from time to time and do not constitute a recommendation to purchase and sale any security nor to engage in any particular investment strategy. The information contained here has been obtained from ...
Two advisors take different approaches in their portfolios to achieve the same goals: low risk and stability.